Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of gastroenterology

• Publication date

  2014-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00535-013-0921-zPMID 24317936
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Once-Daily Simeprevir (TMC435) With Pegylated Interferon and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C: The Randomized PILLAR Study

  2014cited by this paper
• Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.

  2014cited by this paper
• Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma

  2013cited by this paper
• Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4.

  2013cited by this paper
• Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: The randomized PILLAR study

  2013cited by this paper
• Relationship of α-fetoprotein levels and development of hepatocellular carcinoma in hepatitis C patients with liver cirrhosis

  2012cited by this paper
•  Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma.

  2012cited by this paper
• A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy.

  2012cited by this paper
• Telaprevir for previously untreated chronic hepatitis C virus infection.

  2011cited by this paper
• Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon‐based antiviral therapy

  2011cited by this paper
• Clinical characteristics of hepatocellular carcinoma in elderly patients.

  2011cited by this paper
• Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus

  2010cited by this paper
• Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.

  2010cited by this paper
• Epidemiology of hepatocellular carcinoma in Japan

  2009cited by this paper
• Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report

  2009cited by this paper
• Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients.

  2008cited by this paper
• Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma

  2008cited by this paper
• Lymphoid neogenesis and immune infiltration in aged liver

  2008cited by this paper
• Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients

  2007cited by this paper
• Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy

  2005cited by this paper
• Delayed development of hepatocellular carcinoma during long-term follow-up after eradication of hepatitis C virus by interferon therapy.

  2005cited by this paper
• Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon

  2005cited by this paper
• The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma

  2004cited by this paper
• Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3

  2004cited by this paper
• Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

  2004cited by this paper
• Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C.

  2003cited by this paper
• Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan.

  2003influential reference
• Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C

  2002cited by this paper
• A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades

  2002cited by this paper
• Hepatocyte proliferation and risk of hepatocellular carcinoma in cirrhotic patients

  2001cited by this paper
• Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis.

  2001cited by this paper
• Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Japanese patients.

  2000cited by this paper
• Long‐term follow‐up of sustained responders to interferon therapy, in patients with chronic hepatitis C

  2000cited by this paper
• Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long‐term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis

  1999cited by this paper
• Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan

  1999cited by this paper
• Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma.

  1999cited by this paper
• Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

  1999cited by this paper
• Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group.

  1999cited by this paper
• Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients.

  1998cited by this paper
• Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon- Therapy

  1997cited by this paper
• Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

  1995cited by this paper
• Classification of chronic hepatitis: Diagnosis, grading and staging

  1994cited by this paper

• Hepatitis C Patients Over the Age of 75 Should Be Treated With Direct‐Acting Antivirals, as Their Prognosis With Treatment Is Similar to That of Uninfected Healthy Individuals of the Same Age

  2025cites this paper
• Risk for Recurrence After Liver Resection in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Detected After Sustained Virological Response by Direct-Acting Antivirals: A Retrospective Multicenter Study

  2025cites this paper
• Hepatocellular Carcinoma Developing in a Patient 29 Years After Achieving Sustained Virologic Response for Hepatitis C With Interferon Therapy: A Case Report

  2024cites this paper
• Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis C.

  2024cites this paper
• Adjusting to living with chronic liver disease among patients who continue regular healthcare visits for hepatocellular carcinoma surveillance: A grounded theory study.

  2024cites this paper
• Risk of Hepatocellular Carcinoma After Spontaneous Clearance of Hepatitis C Virus and in Noncirrhosis Chronic Hepatitis C Patients With Sustained Virological Response: A Systematic Review.

  2023cites this paper
• Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication

  2022cites this paper
• Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C who achieved a sustained virological response through direct‐acting antiviral agents among the working population in Japan

  2022cites this paper
• Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control

  2021cites this paper
• Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals

  2021cites this paper
• Exploration and time-serial validation of logistic regression models composed of multiple laboratory tests for early detection of HCV-associated hepatocellular carcinoma.

  2021cites this paper
• Management of Hepatitis B Surface Antigen and Hepatitis C Antibody-Positive Patients by Departments Not Specializing in Hepatology at a Suburban University Hospital in Japan: A Single-Center Observational Study

  2020cites this paper
• Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C

  2020cites this paper
• Two Cases of Hepatocellular Carcinoma Arising Over 20 Years after a Sustained Virologic Response Following Interferon Therapy for Chronic Hepatitis C

  2020cites this paper
• Hepatitis C: looking into the future

  2020cites this paper
• Прогностическое значение перфузионной компьютерной томографии в диагностике фиброза и цирроза печени

  2020cites this paper
• JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis

  2020cites this paper
• Prognostic value of computed tomographic perfusion in the diagnosis of liver fibrosis and cirrhosis. Pilot study

  2020cites this paper
• Antidepressant use and hepatocellular carcinoma in patients with hepatitis C who had received interferon therapy: A population-based cohort study.

  2019cites this paper
• Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C

  2019cites this paper
• Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication

  2019cites this paper
• Tanshinone IIA mediates SMAD7-YAP interaction to inhibit liver cancer growth by inactivating the transforming growth factor beta signaling pathway

  2019cites this paper
• Aspartate Aminotransferase-to-Platelet Ratio or Fibros-4 Index Predicts the Development of Hepatocellular Carcinoma in Chronic Hepatitis C Patients with Sustained Virologic Response to Interferon Therapy

  2019cites this paper
• Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents

  2019cites this paper
• Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection

  2018cites this paper
• Case-report: Metastases in a low-stage middle-graded HCC in cleared HCV infection, non-cirrhotic liver: Surgical therapy

  2018cites this paper
• Rapidly growing hepatocellular carcinoma after direct-acting antiviral treatment of chronic hepatitis C

  2018cites this paper
• Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals

  2018cites this paper
• Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance

  2018cites this paper
• Increased Duodenal Iron Absorption through Upregulation of Ferroportin 1 due to the Decrement in Serum Hepcidin in Patients with Chronic Hepatitis C

  2018cites this paper
• An intronic single nucleotide polymorphism in the MUTYH gene is associated with increased risk for HCV‐induced hepatocellular carcinoma

  2018cites this paper
• Predictors of hepatocellular carcinoma occurrence after direct‐acting antiviral therapy in patients with hepatitis C virus infection

  2018cites this paper
• Development of Hepatocellular Carcinoma After Viral Clearance in Chronic Hepatitis C Patients : A Need for Continual Surveillance

  2018influential citation
• The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4

  2017cites this paper
• Hepatitis C virus infection triggers a tumor‐like glutamine metabolism

  2017cites this paper
• Predictors of treatment efficacy and ALT non‐normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2

  2017cites this paper
• Hepatocellular carcinoma in patients without advanced fibrosis after HCV eradication antiviral treatment.

  2017influential citation
• Post‐treatment levels of α‐fetoprotein predict long‐term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C

  2017cites this paper
• The Direct-Acting Antivirals for Hepatitis C Virus and the Risk for Hepatocellular Carcinoma.

  2017cites this paper
• Hepatitis C in the EU: setting the terms for elimination.

  2017cites this paper
• American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection.

  2017cites this paper
• Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.

  2017cites this paper
• Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.

  2017cites this paper
• Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals

  2017cites this paper
• Long-term clinical, histological and virological outcomes after sustained virologic response in patients with chronic hepatitis C

  2017cites this paper
• Incidence et caractéristiques du carcinome hépatocellulaire après un traitement par antiviraux directs

  2017cites this paper
• Long-term follow-up of patients with chronic hepatitis C treated with &agr;-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response

  2017cites this paper
• Mutations in hepatitis B virus polymerase are associated with the postoperative survival of hepatocellular carcinoma patients

  2017cites this paper
• Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C

  2016cites this paper
• A novel glycobiomarker, Wisteria floribunda agglutinin macrophage colony‐stimulating factor receptor, for predicting carcinogenesis of liver cirrhosis

  2016cites this paper
• The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?

  2016influential citation
• HCC: Where Does HCV Therapy Play a Role?

  2016cites this paper
• Nonzero Risk of Hepatocellular Carcinoma Even after Sustained Virological Response

  2016influential citation
• Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection

  2016cites this paper
• Liver stiffness‐based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy

  2016cites this paper
• Outcomes of Interferon/Ribavirin Therapy in Patients with HCV Defined by Expression of Plasma Soluble Human Leukocyte Antigen-G but Not IL-37

  2016cites this paper
• Hepatitis C Genotype Prevalence in Monastir Region, Tunisia: Correlation between 5′ Untranslated Region (5′UTR), Non-structural 5B (NS5B), and Core Sequences in HCV Subtyping

  2016cites this paper
• Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication

  2016cites this paper
• Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index

  2016cites this paper
• Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C.

  2016cites this paper
• Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma.

  2016cites this paper
• Impact of hepatitis C virus eradication on hepatocellular carcinogenesis

  2015cites this paper
• Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development.

  2015cites this paper
• Abstract. The outcome of antiviral therapy is associated with viral and host factors. In the present study, the association between MHC class I-related chain B (MICB) genotypes and therapeutic response to pegylated interferon plus ribavirin

  2015cites this paper
• MHC class I-related chain B gene polymorphism is associated with virological response to pegylated interferon plus ribavirin therapy in patients with chronic hepatitis C infection.

  2015cites this paper
• Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin

  2015cites this paper
• Development of Hepatocellular Carcinoma in Chronic Hepatitis C Patients 20 Years after Achieving a Sustained Virological Response with Interferon Therapy: A Report of Two Cases

  2015cites this paper
• Role of antiviral therapy in patients with chronic hepatitis B or C virus in preventing the development of hepatocellular carcinoma

  2015cites this paper
• Oncogenic viruses and hepatocellular carcinoma.

  2015cites this paper
• Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade.

  2015cites this paper
• Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?

  2014cites this paper
• How much management is necessary? Sustaining the benefit of achieving a sustained virologic response to hepatitis C

  2014cites this paper
• The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

  2014cites this paper
• Piecing together the key players of fibrosis in chronic hepatitis C: what roles do non-hepatic liver resident cell types play?

  2014cites this paper